Maricrio (Omeprazole)

Omeprazole acts by binding irreversibly to the H⁺/K⁺‑ATPase enzyme, also known as the gastric proton pump, on the surface of parietal cells. This inhibition blocks the final step of acid secretion, leading to a sustained increase in gastric pH and a reduction in both basal and stimulated acid output.

The appropriate dose of Maricrio is determined by the prescribing healthcare professional based on the specific indication, patient characteristics, and clinical response. Patients should follow the dosage instructions provided by their prescriber and not adjust the amount without medical guidance.

Safety data for omeprazole during pregnancy and lactation are limited. It should only be used if the potential benefit justifies any possible risk to the fetus or infant. Women who are pregnant, planning to become pregnant, or breastfeeding should discuss the risks and alternatives with their healthcare provider.

To place an order, submit an enquiry on the Maricrio product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, confirming trade or institutional credentials before providing pricing, availability, shipping details, and any necessary import documentation.

Maricrio (omeprazole) belongs to the same class as esomeprazole, lansoprazole, pantoprazole and rabeprazole. All share a similar mechanism of inhibiting the gastric proton pump, but they differ slightly in pharmacokinetic profiles, potency and drug‑interaction potential. Choice of agent often depends on physician preference, patient response, and specific interaction considerations.

Maricrio tablets should be stored at ambient temperature, preferably below 25 °C. Keep the product in its original packaging, protect it from moisture and direct sunlight, and ensure the container is tightly closed to maintain stability throughout its shelf life.

Maricrio is taken orally, usually as a whole tablet swallowed with a glass of water. It is generally recommended to take the medication before a meal, often in the morning, unless the prescriber advises a different schedule based on the therapeutic goal.

Serious but uncommon risks include Clostridioides difficile‑associated colitis, severe allergic reactions such as anaphylaxis, hypomagnesemia with long‑term use, and an increased incidence of bone fractures. Patients should seek immediate medical attention if they experience persistent diarrhea, severe rash, swelling, or unexplained muscle weakness.

Maricrio should be avoided in individuals with a known hypersensitivity to omeprazole or any component of the formulation. Caution is also advised for patients with severe liver disease, those taking medications that rely on gastric acidity for absorption, and patients with a history of certain bone disorders when used long‑term.